Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chen, Lee H ^a   Kuo, Wen Hung ^b   Tsai, Mong Hsun ^a   Chen, Pei Chun ^c   Hsiao, Chuhsing K ^a   Chuang, Eric Y ^a   Chang, Li Yun ^b   Hsieh, Fon Jou ^b   Lai, Liang Chuan ^a   Chang, King Jen ^b,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c PROVIDENCE UNIVERSITY   (Taiwan)

^d CHENG CHING GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; EPHRIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; DPEP3 GENE; FAM43A GENE; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC PREDISPOSITION; GRB7 GENE; HUMAN; HUMAN TISSUE; MORC2 GENE; ONCOGENE; PREDICTION; PRKAG3 GENE; PROGNOSIS; PROTEIN FUNCTION; RECURRENCE RISK; RECURRENT CANCER; SCL22A23 GENE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TAIWAN;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS; RECURRENCE; RISK FACTORS; SIGNAL TRANSDUCTION; TAIWAN;

EID: 82255182155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028222     Document Type: Article

References (32)

1. Bureau of Health Promotion DoH, ROC, Taiwan (2010) Cancer Registry Annual Report 2007.
2. Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, et al. (2009) Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9: 192.
3. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, et al. (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661-671.
4. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, et al. (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996.
5. Cleator S, Heller W, Coombes RC, (2007) Triple-negative breast cancer: therapeutic options. The Lancet Oncology 8: 235-244.
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
8. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, et al. (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16 (Suppl 2): S72-77.
9. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, et al. (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37: 1217-1226.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
11. Hu Z, Fan C, Oh D, Marron J, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
12. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, et al. (2003) Gene expression predictors of breast cancer outcomes. The Lancet 361: 1590-1596.
13. van't Veer L, Dai H, van de Vijver M, He Y, Hart A, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530- 536.
14. Ma X-J, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616.
15. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, et al. (2006) Concordance among Gene-Expression-Based Predictors for Breast Cancer. N Engl J Med 355: 560-569.
16. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, et al. (2002) A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. N Engl J Med 347: 1999-2009.
17. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. The Lancet 365: 671-679.
18. West M, Blanchette C, Dressman H, Huang E, Ishida S, et al. (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America 98: 11462-11467.
19. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
20. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98: 10869-10874.
22. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100: 8418-8423.
23. Peppercorn J, Perou CM, Carey LA, (2008) Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. Cancer Investigation 26: 1-10.
24. Marsh S, McLeod HL, (2001) Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1: 175-178 discussion, 179-181.
25. Saif MW, Sandoval A, (2008) Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Cutan Ocul Toxicol 27: 311-315.
26. Sato K, Morita M, Ichikawa C, Takahashi H, Toriyama M, (2008) Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells. Biosci Biotechnol Biochem 72: 2589-2597.
27. Zhang W, Zeng X, Briggs KJ, Beaty R, Simons B, et al. (2010) A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 29: 2467-2476.
28. Wykosky J, Gibo DM, Debinski W, (2007) A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor, Äìexpressing tumor cells. Molecular Cancer Therapeutics 6: 3208-3218.
29. Cheung PCF, Salt IP, Davies SP, Hardie DG, Carling D, (2000) Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochemical Journal 346: 659-669.
30. Milan D, Jeon JT, Looft C, Amarger V, Robic A, et al. (2000) A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 288: 1248-1251.
31. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, et al. (2008) Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer 122: 1557-1566.
32. Deblois G, Hall JA, Perry M-C, Laganiere J, Ghahremani M, et al. (2009) Genome-Wide Identification of Direct Target Genes Implicates Estrogen-Related Receptor {alpha} as a Determinant of Breast Cancer Heterogeneity. Cancer Research 69: 6149-6157.